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The purpose of this review was to evaluate the streng h of evidence for a relationship between 
risk of mortality and frequent and ongoing insomnia using a meta-analytic strategy.  
Seventeen studies, including a total of 36,938,981 individuals followed up for a mean of 11.6 
years, reporting the investigation of the association between mortality and frequent (≥3 
nights/week), ongoing (≥1 month) insomnia were identified.  
There was no difference in the odds of mortality for those individuals with symptoms of 
insomnia when compared to those without symptoms (OR= 1.06, 95%CI=0.61-1.84, p=.84). 
This finding was echoed in the assessment of the rate of mortality in those with and without 
symptoms of insomnia using the outcomes of multivariate models, with the most complete 
adjustment for potential confounders, as reported by the individual studies included in this 
meta-analysis (HR= 1.07, 95%CI=.96-.1.19, p=.22). Additional analyses revealed a tendency 
for an increased risk of mortality associated with hypnotic use.  
The current evidence reinforces the use of cognitive therapy, within a CBTi framework, as a 
frontline non-pharmacological treatment for insomnia to reassure patients their longevity will 
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As the most common sleep disorder, insomnia affects the lives of 10-30% of the 
population (1) which at a conservative estimate equates to around 2.5 million individuals 
living in Australia alone and 770 million world wide. Insomnia is characterized by a 
subjective report of difficulty falling asleep, maintaining sleep or nonrestorative sleep coupled 
with daytime impairment (2). The impact of the disorder on the quality of the lives of 
sufferers is widespread across both psychological and physiological functioning. Impaired 
daytime functioning including fatigue, problems with cognitive performance, complaints of 
depressed mood and feelings of anxiety, difficulty maintaining social relationships and ill 
health are all hallmark characteristics of the disorder (2, 3). Growing empirical evidence, 
including meta-analytic, suggests that insomnia is strongly associated with significant medical 
morbidity including depression (4, 5), dementia (6) and cardio-metabolic outcomes including 
hypertension (7-9), and diabetes (10, 11), and inflammatory processes (12), however it 
remains unclear whether the risk of mortality is increased for those suffering from insomnia.  
Various theoretical models propose an increased risk of mortality attributed to 
insomnia either from a psychological or physiological standpoint. It is well established that 
insomnia is an independent risk factor for the development of various psychological 
disorders, namely depression and anxiety (13-15). Although the mechanisms by which 
insomnia precedes the development of psychological d sorders is unknown (16), the 
comorbidity of these disorders is proposed to increase risk of mortality in those with 
insomnia. This is presumably due to the elevated rates of self-harm and suicide characteristic 
of these psychological disorders (17).  
Findings from physiological studies also suggest a proposed mechanism for increased 














hypothalamic-pituitary-adrenal (HPA) axis and autonomic nervous system (sympathetic 
division), including increased 24h metabolic rate, increased heart rate and impaired heart rate 
variability, is increased in those suffering insomnia (18-21). This physiological over 
activation has been inconsistently associated with hypertension, diabetes and ultimately 
increased mortality (22, 23).  
 However empirical support for the notion that mortality risk is increased in insomnia 
has been inconsistent. Despite some support from small- cale longitudinal and prospective 
cohort studies (24, 25), longitudinal research conducted with large samples (N>300k) of 
diverse age ranges have reported no association or even a negative association between risk of 
mortality and insomnia (26, 27). For instance, Chien and colleagues (24) and Vgontzas et al. 
(25) both found mortality risk was significantly increased for those suffering insomnia in their 
prospective cohort and longitudinal studies with ~14-year follow up. Contrary to these 
findings, Gapstur and colleagues (26) reported no support for the association between 
insomnia frequency and fatal prostate cancer at 28 years of follow up in their large 
prospective cohort study of U.S. adults. Kripke et al. (27) sampled over 1.1 million 
individuals and found a reduced mortality rate for those individuals complaining of insomnia 
symptoms on 6-year follow up. Given this disparity, firm conclusions regarding mortality risk 
and its association with insomnia have not been able to be drawn. 
 The body of literature exploring the association between mortality and insomnia has 
numerous flaws which likely contribute to the inconsistent findings including small numbers 
of deaths, lack of measurement or statistical control fo  factors confounding the relationship 
between mortality and insomnia, such as lifestyle factors (i.e. smoking, obesity) and 
medication use particularly hypnotics (28), loss to follow up and typically small effect sizes. 
More importantly, the majority of studies focus on assessing the relationship between 














duration is characteristic of some types of insomnia (29), it is certainly not the case types of 
insomnia associated with misperception of objective sle p duration and quality. In our earlier 
work (30), we found that 57% of individuals diagnosed with insomnia had an objective sleep 
duration of more than 6hrs (total sample N = 91). Likewise, Vgontzas and colleagues (25) 
reported objective sleep duration longer than 6 hours in 40% of their sample of 55 individuals 
diagnosed with insomnia. Furthermore, most studies also do not account for the frequency 
(nights/week of insomnia symptoms) or severity of insomnia. Given these major 
shortcomings, any conclusions, which may be drawn about the association between insomnia 
and increased risk of mortality, are limited. The question of whether insomnia is associated 
with an increased risk for death remains unanswered.  
 The importance of understanding whether insomnia is associated with an increased 
risk for death should not be underestimated and has significant implications for public health 
and the treatment of insomnia. Non-pharmacological interventions are considered best 
practice for the treatment of ongoing insomnia. Thegold-standard treatment, Cognitive 
Behaviour Therapy (CBTi), produces robust and durable therapeutic improvements, 
extending well beyond the period of therapy, which are typically superior to pharmacological 
preparations without the known side effects and issue  of tolerance and dependence (31-33). 
Given CBTi aims to modify poor sleep habits, regulate sleep/wake schedules, correct faulty 
beliefs and attitudes about sleep, and develop adaptive coping skills (34), the incorporation of 
education around the relationship between insomnia a d risk for death is likely to hold 
significant therapeutic weight. If indeed there is an increased mortality risk for those suffering 
from insomnia, successful treatment, preferably with Cognitive Behaviour Therapy (CBTi), 
may also reduce morality risk. On the other hand, if there is no increased mortality risk 
associated with insomnia, this would form a valuable and therapeutic aspect of cognitive 














insomnia with many sufferers subscribing to the underlying belief that insomnia is 
detrimental to health (34). To the authors’ knowledg , the extent to which this belief extends 
to increased risk of mortality per se remains to be empirically investigated. Nevertheless the 
anecdotal clinical experience of the authors’ is that is belief is expressed by many patients, 
particularly older adults with comorbid medical conditions. The incorporation of the 
psychoeducation around the lack of increased mortality risk in insomnia would be very 
therapeutic in a cognitive context to reduce anxiety about insomnia and thereby potentially 
boost the efficacy of treatment. In that case althoug  it would not reduce mortality risk, many 
therapeutic benefits occur with successful treatmen of insomnia with BTi such as reduced 
fatigue, depressive, anxiety, and stress symptoms, and generally improved quality of life (35, 
36).   
 The purpose of this review was to evaluate the strength of evidence for a relationship 
between risk of mortality and frequent (≥3 nights/week) and ongoing (≥1 month) insomnia. 
Data from studies investigating the association betwe n mortality and insomnia was gathered 
and a meta-analytic strategy used to provide a quantitative summary of data on this topic. 
Meta-analysis of similar and methodologically sound studies is considered to provide a high 
level of evidence (37) and potentially a more precis  estimate of the underlying ‘true effect’ 




A quantitative summary of data from studies investigating the association between 
symptoms of insomnia and the risk of mortality is provided using a meta-analytic strategy.  














 Electronic databases, including MEDLINE, Web of Scien e, OvidSP, PsycInfo, 
PubMED, and online journals (e.g. SLEEP, Archives of General Psychiatry, Circulation etc.) 
were used to identify and retrieve research articles exploring the relationship between 
insomnia and the risk of mortality. Relevant publicat ons were located in all journals using an 
advanced search with the search terms insomnia [Title/Abstract] AND mortality [Text word]. 
The search was also expanded by manually identifying relevant publications from the 
reference lists of retrieved literature. 
Publications were included in this review if they met the following criteria: 1) 
published in a peer-reviewed journal in English, 2) utilized an adult sample (18 years and 
over), 3) included at least one measure of insomnia symptoms (either subjective) and 
mortality (all cause or specific), 4) symptoms of insomnia must be frequent (reported on at 
least 3 nights per week) and ongoing(reported for at least one month), and 5) authors provided 
appropriate statistics from which mortality risk can be assessed (i.e. number of 
deaths/survival in insomnia and no-insomnia groups, or hazard ratios and accompanying 95% 
confidence intervals). The literature search was conducted from April to May, 2017.  
Statistical analyses 
Data extraction and quality assessment 
 Insomnia symptoms were assessed primarily using subjective reports consistent with 
the diagnostic criteria for insomnia (2, 3) and included at least one of the following; difficulty 
falling asleep, staying asleep, or waking up too early in the morning with or without 
accompanying impairments to daytime functioning. These symptoms were required to be 
frequent (≥3 nights/week) and ongoing (≥1 month) and were either self-reported by the study 
participants, clinical sleep specialist or psychiatrist. The date and cause of mortality was 














 The quality of the included studies was assessed across five different domains 
proposed to be sources of potential bias (39). The domains assessed included study 
participation (i.e. recruited sample is representative of the population of interest), study 
attrition, satisfactory measurement of the outcome variable, measurement of confounding 
variables and adequate statistical analyses. Hayden and colleagues (39) propose a sixth 
domain of potential bias, adequate measurement of the prognostic factor, however given 
stringent criteria for the assessment of insomnia are included in the inclusion criteria, the 
included studies were not assessed on this domain. The ratings for included studies are 
presented in Table 1. The retrieved studies were revi w d for eligibility independently by the 
authors (NL and LL) in an un-blinded and standardise  manner in accordance with the 
selection criteria. Instances of disagreement betwen the reviewers were resolved by 
consensus. The same approach was used when assessing the quality of the included studies. 
Meta-analyses 
All analyses were conducted using Comprehensive Meta-analysis, version 3.0 (40). 
Comprehensive Meta-analysis is a leading meta-analysis program that has capacity to use a 
range of different data formats, including the use of reported effect sizes (i.e. hazard ratio) or 
to calculate effect sizes from commonly reported stati tics such as death and survival data. 
The software provides standard meta-analysis methods including the reporting of the forest 
plot and accompanying statistics. The tool also supports additional analyses including 
subgroup, moderator, and publication bias analyses. 
Un-adjusted analyses 
To assess the risk of mortality associated with insomnia independent of any other 
factors that might affect risk, odds ratios (OR) and ssociated 95% confidence intervals for 
all-cause mortality were calculated for each study from the extracted death and survival data 















 The aim of these analyses was to assess the risk of mortality associated with insomnia 
above other factors that potentially confound this as ociation. The included studies used 
different outcome measures to assess the association between insomnia and mortality when 
accounting for confounding variables. Some studies reported relative risk while the majority 
reported hazard ratio. The present meta-analysis used hazard ratio (HR) as the main outcome 
measure. The HR of the multivariate models with the most complete adjustment for potential 
confounders from each included study were used for these analyses. The confounding 
variables included in the models is shown for the individual studies in Table 1.  
Additional analyses were also undertaken to examine whether mortality risk differed 
according to shared characteristics of the included stu ies and potential moderating factors 
(i.e. characteristics of the study population and design, as well as confounding factors such 
lifestyle factors, including excessive alcohol consumption, smoking, obesity, and hypnotic 
use).  
The unadjusted and adjusted analyses obtained pooled OR/HR estimates using inverse 
variance weights in random-effects models. OR/HR for insomnia symptoms and mortality 
outcomes were pooled for studies with similar, good sleeper, reference categories. 
Interpretation of main outcome measures 
To assist in the interpretation of the outcomes of this meta-analyses, it is relevant to 
provide a brief guide to the interpretation of odds ratios (outcome of unadjusted analyses) and 
hazard ratios (outcome of adjusted analyses).  
Odds Ratio (OR) represents the odds than an outcome will occur given a particular 
exposure compared to the odds of the outcome occurring in the absence of that exposure, 
whereas Hazard Ratio (HR) refers to the instantaneous risk. In the context of this meta-














insomnia compared to those with no symptoms. Unlike OR, HR is not a cumulative estimate. 
HR reflects the estimated risk of mortality for those with symptoms of insomnia, relative to 
those with no symptoms, at any given point of time. The interpretation of OR and HR is 
similar, keeping in mind the distinction of time periods. Increased odds of mortality, and a 
faster rate of death, for those with symptoms of insomnia relative to those without, is 
indicated by an OR and HR greater than 1, respectively. OR and HR less than one indicates a 
protective effect with a decreased likelihood of mortality, and slower rate of death, for those 
with symptoms of insomnia compared to those with no symptoms, respectively. It is 
important to note these ratios are comparisons between two groups and give no indication of 
how quickly death occurs in either group.  
 
Heterogeneity and publication biases 
 The Q-statistic (also referred to as Cochrane’s Q) provided an indication of the 
variability of the effect sizes (41). When significant, the Q-statistic indicates the variability in 
study effect size is greater than expected by chance. It is important to note the Q-statistic is 
vulnerable to bias from sample size, therefore it is often interpreted in conjunction with the I2 
statistic which quantifies the degree of heterogeneity. In the current analyses, I2 is reported for 
instances when the Q-statistic is significant.   
Funnel plots of the effect size relative to standard er or were used to assess possible 
publication bias. Funnel plots which appear symmetrical upon visual inspection suggest no 
bias is present. 
  
Results 
Selection of studies 
 Figure 1 shows the flow of the literature search process. Four hundred and thirty eight 














mortality. Eighty-eight papers were excluded (reasons f r exclusion are listed in Figure 1). A 
total of 17 studies met inclusion criteria and were ntered into the meta-analysis.  
<Insert Figure 1 about here> 
Characteristics of included studies 
The characteristics of the included studies are summarised in Table 1. A total of 
36,938,981 subjects were included in the meta-analysis, of whom 366,024 (approximately 
10%) were suffering from insomnia. Eight of the 17 studies included the presence of daytime 
impairments in their definition of insomnia. Sample sizes ranged from ~150 to >35,000,000. 
Follow up periods varied from 2.2 years to 28 years, with a mean follow up of 11.6 (SD=2.3). 
The included studies were conducted in eight countries across the world including the United 
States (N=7), Europe (N=3), and Asia (N=7). Most of the included papers assessed insomnia 
as self-reported according to the diagnostic criteria (DSM-IV or ICSD-IV). Of these studies, 
four required self-reported symptoms to be confirmed by a sleep physician or psychiatrist (42-
45). Most of the studies used definitions including difficulty initiating and/or maintaining 
sleep, and/or waking too early (46-52), while others were broad in their definition, such as 
presence of a complaint of insomnia (24-27).  
The quality of the included studies varied. Collectively, the majority of studies (82%) 
measured the outcome variable satisfactorily with many (47%) also having measured 
confounding variables adequately. Unfortunately, only a few studies accounted adequately for 
study participation (29%) and statistical analyses (29%) with none of the included studies 
describing or accounting well for attrition.  
Insomnia and mortality risk 
Unadjusted analysis 
 The weighted rate of mortality among those suffering from insomnia was 1.8% 














and associated 95% confidence intervals calculated for each study from extracted death and 
survival data. There was no difference in the odds of mortality for those individuals with 
symptoms of insomnia when compared to those without symptoms (OR= 1.06, 95%CI=0.61-
1.84). Heterogeneity between the studies was high and significant (Q=2680.91, I2=99.52, 
p<.001). The results of the meta-analysis are further summarised in Table 2 below.  
It is possible the former odds of mortality is merely a reproduction of the results of 
one individual study (43), which accounts for 96% of the total sample size of the analysis. 
Therefore the analysis has been replicated with the exclusion of this study. As a result, the 
odds of mortality for those individuals with symptoms of insomnia increased marginally 
relative to those without symptoms (OR= 1.16, 95%CI=0.81-1.67). The heterogeneity 
between studies remained high and significant (Q=439.65, I2=97.27, p<.001).  
<Insert Table 2 about here> 
Adjusted analysis 
 This analysis was conducted using the HR reported in the individual studies for the 
multivariate models with the most complete adjustment for potential confounders. These 
results are consistent with the unadjusted analysis, revealing the rate of mortality was 
comparable for those with symptoms insomnia when compared to those without symptoms 
(HR= 1.07, 95%CI=.96-.1.19). Heterogeneity between the studies was high and significant 
(Q=156.31, I2=88.48, p<.001), with I2 suggesting at least 88% of the variance is generated 
from real differences between studies at the study level. The results of the meta-analysis are 
further summarised in Table 3 below. Given the heterog neity observed additional analyses 
were conducted to explore potential differences betwe n studies and moderating factors 
which may explain this heterogeneity.  
<Insert Table 3 about here> 














 Additional analyses were conducted to investigate pot ntial differences between 
studies by grouping studies according to shared chara teristics including composition of the 
sample (i.e. age, sex, country of cohort [European, no -European], cohort type [community-
based, patient sample]), and methodological considerations (i.e. sample size, length of follow 
up, presence of daytime impairments included in the definition of insomnia, account for 
confounding variables including at least one lifestyle factor [e.g. excessive alcohol 
consumption, smoking, obesity] and use of hypnotic medications). The fixed effects analyses 
reveal those studies with female, community-based samples show a tendency to report a 
reduced rate of mortality when compared to studies with male, patient-based samples (Table 
4). Studies with a shorter duration of follow up, and somewhat larger sample size also tended 
to report a decreased rate of mortality. The reported ate of mortality is lower in those studies 
that did not include the presence of daytime impairments in their definition of insomnia and 
focused solely on nocturnal symptoms. Studies that statistically accounted for a minimum of 
at least one lifestyle factor and those that controlled for the use of hypnotic medications 
reported a consistent and reduced rate of mortality.  
<Insert Table 4 about here> 
Publication bias 
 Funnel plots of the effect size and standard error were performed for both the 
unadjusted and adjusted analyses to investigate possible publication bias. The funnel plot for 
the unadjusted analyses appeared symmetrical upon visual inspection indicating the absence 
of publication bias. However, the funnel plot of the adjusted analyses tended to show a 
higher concentration of studies on the right side of the mean. This indicates that smaller 
studies (which appear towards the bottom) with larger than average effects are more likely to 
be published. Therefore, there is concern that studies that fall to the left side of the mean may 
exist but are missing from the analysis. The Duval and Tweedie’s (53) ‘Trim and Fill’ 














and the re-computation of the combined effect after adding them to the analysis. The ‘Trim 
and Fill’ method initially locates the unbiased effect through the iterative trimming of the 
asymmetric studies from the right-hand side of the funnel plot. The method then fills the plot 
by re-inserting the trimmed studies on the right-hand side as well as the imputed studies on 
the left-side of the mean. Using this method 5 studies have been deemed as missing and have 
therefore been imputed into the plot shown in Figure 2. Under the random effect model the 
observed HR was 1.07 (.96-1.19). Using the ‘Trim and Fill” method the adjusted HR is 
decreased to 0.98 (.88-1.09).  
<Insert Figure 2 about here> 
 
Discussion 
 The present study is the first to use a meta-analytic strategy to summarise data from 
published studies investigating the relationship betwe n mortality and frequent (≥3 
nights/week), ongoing (≥1 month) insomnia and in doing so evaluate the streng h of evidence 
for an association between the two. These results provide support for the lack of an 
association between increased risk of mortality and insomnia. The meta-analysis of 17 studies, 
including a total of 36,938,981 individuals followed up for a mean of 11.6 years, revealed the 
risk of mortality did not differ significantly for those with symptoms of insomnia when 
compared to those without symptoms. This finding was echoed in the assessment of the rate 
of mortality in those with and without symptoms of insomnia using the outcomes of 
multivariate models, with the most complete adjustment for potential confounders, as reported 
by the individual studies included in this meta-analysis.  
 The current meta-analytic findings authenticate thoutcomes of recent large-scale 
longitudinal research, which report no association between mortality and insomnia (26, 27, 
46). However, these findings are contrary to some of the literature reviews on this topic. This 














assess the relationship between mortality and sleep duration, not insomnia (27). Although 
objective short sleep duration is associated with a host of adverse health outcomes and an 
increased risk of mortality (29), short sleep is not equivalent to insomnia (25, 30). Objectively 
short sleep duration is typically not observed among those suffering the more prevalent types 
of insomnia, which are characterised by the misperception of sleep duration and quality. 
Furthermore, short sleep duration can be self-imposed and be present in individuals without 
symptoms of sleep disturbance (54, 55). Therefore it is inappropriate to extend the association 
of increased mortality observed in those with objectiv  short sleep duration to insomnia. It is 
recommended future work report objective sleep duration to facilitate an understanding of the 
role sleep duration plays in the association between insomnia and mortality.  
Additional analyses were conducted to examine whether mortality risk differed according 
to characteristics of the study population and design, and confounding factors including 
excessive alcohol consumption, smoking, obesity, and hypnotic use. These analyses suggest a 
tendency for a reduced rate of mortality among community-dwelling females when compared 
to male patients. Studies with a shorter duration to follow-up and larger sample sizes, reported 
a diminished rate of mortality among those reporting symptoms of insomnia relative to those 
who did not.  
Of particular interest are the implications for the association between mortality and 
insomnia when considering the criteria used to define insomnia and the influence of hypnotic 
use. The studies that included the presence of daytime impairments in their definition of 
insomnia reported a 56% chance of those with insomnia dying before those without, where a 
50% chance would indicate that there is no difference i  the rate of death between those with 
and without insomnia. In contrast, those studies that focused their definition of insomnia on 
nocturnal symptoms alone reported a 49% probability, or very little difference, of those with 














it is plausible an increased mortality when daytime symptoms are present may be attributed to 
the relationships between daytime symptoms of depressed mood, anxiety, fatigue and ill 
health, and quality of life with mortality risk. Itmay also be that daytime symptoms index a 
more severe or vulnerable type of insomnia which may confer greater health risk. To the 
authors’ knowledge, this assessment is unique to the present study and needs to be replicated.  
Hypnotic use also influences the rate of mortality between those with symptoms of 
insomnia and those without. The chance of those with symptoms of insomnia dying before 
those without was 49% among the studies that controlled for the use of hypnotic preparations. 
This chance was increased by 6% among studies that failed to account for hypnotic use. The 
increased rate of mortality associated with hypnotic use has also been reported by others. 
Kripke and colleagues (27) reported prescription sleeping pill use was significantly associated 
with mortality after control for insomnia in their large sample of over 1.1 million adults. 
Likewise Chen and colleagues (56) found consistent, increased mortality risk among those 
who use hypnotics frequently, even after controlling for insomnia. Therefore, when hypnotic 
medications are not controlled is it likely that the insomnia group have a much higher usage 
rate of these medications and it is the medications which are associated with increasing 
mortality risk not insomnia. Unfortunately the interpretation for the implications of potential 
risk of increased mortality risk associated with acute versus chronic hypnotic use is limited 
due to the considerable variability in the duration of hypnotic use among the studies included 
in this meta-analysis.  
The current findings have significant implications for the treatment of insomnia. At 
present, the evidences does not support an increased ri k of mortality from insomnia 
symptoms, even among those suffering from daytime ipa rments. This reinforces the 
strength of cognitive therapy for reassuring patients of no impact on their longevity as a 














insomnia is detrimental to their health, a core cognitive feature of insomnia (34). As 
previously mentioned the extent to which this belief extends to increased risk of mortality 
remains to be empirically tested, but anecdotal evidence of many clinicians supports the 
expression of this sentiment by many patients. This knowledge and reassurance may help 
reduce their anxiety related to this matter and in oing so break the cycle of insomnia. The 
focus should therefore be on improvement of sleep efficiency, daytime symptoms and overall 
quality of life as addressed by CBTi. 
Limitations and directions for future research 
 These analyses should be interpreted with some degree of caution given several 
limitations. The current review identified only 17 studies that examined the relationship 
between mortality and frequent, ongoing insomnia. These studies typically had short follow 
up durations (mean=11.6yrs, SD=2.3, range=2.2-28yrs) and few deaths. Firm conclusions 
about the relationship between mortality and insomnia cannot be established until more 
research with longer follow up periods are conducted and published. Many of the studies 
included in this review differed with respect to their definition of insomnia. Although most 
assessed the presence of insomnia as self-reported according to the diagnostic criteria (DSM-
IV or ICSD-IV), several studies were very broad in their definition with less than half 
acknowledging and including the presence of daytime i pairments in addition to nocturnal 
symptoms. Ideally insomnia should be assessed in accordance with diagnostic criteria rather 
than merely as the presence of a complaint of ‘insomnia’ or difficulties initiating or 
maintaining sleep. Furthermore, several studies assessed self-reported sleep quality using a 
single survey item which requires the individual to pr vide a retrospective recall of their sleep. 
It is recommended that prospective self-reported slep be assessed using sleep diaries which 
provide more accurate information regarding sleep quality than a single survey item that 














assessment of subjective sleep and should be implement d in the context of large prospective 
cohort studies to collect better quality data relating to subjective sleep (57). It is also 
noteworthy that studies which assessed insomnia symptoms based on self-report did not 
assess the cognitive status of the participants. Cognitive status may impact self-reported 
insomnia symptoms and constitutes a medical morbidity. All of the included studies 
controlled for the influence of comorbid physical conditions, however a number of potentially 
confounding variables, such as use of hypnotic preparations (58), severity of insomnia, 
presence of comorbid psychiatric disorders (e.g. depression, anxiety), and lifestyle factors (e.g. 
excessive alcohol consumption, smoking) known to increase the risk of mortality were either 
not measured or statistically controlled in some of the studies included in this review. It is 
recommended that future research evaluate the risk of mortality and insomnia independently 
from other related variables.  
Conclusions 
The association between mortality and frequent, ongoing insomnia was not supported 
in the current quantitative summary of the literatue. This meta-analysis revealed the risk of 
mortality did not differ significant for those with symptoms of insomnia when compared to 
those without symptoms. The lack of an association between mortality and insomnia was also 
observed when using the most complete adjustment for potential confounders, as reported by 
the individuals studies included in this meta-analysis. The current evidence reinforces the use 
of cognitive therapy, within a CBTi framework, as a frontline non-pharmacological treatment 
for insomnia to reassure patients their longevity will not be impacted as a consequence of 
suffering from insomnia. It is recommended treatment should focus on improvement of sleep 































1) There is insufficient evidence to support an association between mortality and 
frequent (≥3 nights/week), ongoing (≥1 month) insomnia. 
2) The current findings emphasise the use of cognitive therapy, within a CBTi 
framework, as a frontline non-pharmacological treatment for insomnia to reassure 
patients their longevity will not be impacted as a consequence of suffering from 
insomnia. Treatment should focus on improvement of sleep efficiency, daytime 





1) More studies investigating the relationship between mortality and frequent (≥3 
nights/week), ongoing (≥1 month) insomnia, with long follow up periods, are 
required.  
2) Ideally, future research should evaluate the risk of m rtality and insomnia 
independently from other related variables, such as use of hypnotic preparations and 
presence of comorbid psychiatric disorders (e.g. depression, anxiety), and lifestyle 














3) Sleep diaries provide the gold-standard assessment of subjective sleep and should be 
implemented in the context of large prospective cohort studies to collect better quality 
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dwelling in the 
U.S.C 





Self-reported – At least 
one of the following on 
16-30 nights per month 
“Have trouble falling 
asleep”, “wake up 
during the night and 
have difficulty getting 
back to sleep”, “wake 
up too early in the 
morning and unable to 
get back to sleep” or 
“take sleeping pills or 
other medication to 






1163 Age, sex, ethnicity, 
smoking status, AHI, 
antidepressant use, 
BMI, hypertension, 
total cholesterol and 
HDL, blood pressure, 
diabetes 
All cause and 






















4064 (55.8) M=73.8 
(5.7)  
M=7.0 (2.1) Self-reported- 
Pittsburgh Sleep 
Quality Index responses 
used to diagnose 
insomnia as per DSM-
VI criteria 
National death 
registry of the 
Department of 
Health, Taiwan 
1004 Age, sex, education, 
living and marital 





poor sleep, acute and 
chronic insomnia, 
hypnotic use, total 
sleep time, presence of 
major systemic illness 
All cause and 
























3430 (49.7) ≥35 Median=15.9 
(IQ=  
 13.1- 16.9) 
Self-reported – “How 
frequent is your 
insomnia?” with 4 
response alternatives 
including no insomnia, 
occasional insomnia (2-
3 times/month), 








901 Age, sex, BMI, 
smoking status, alcohol 
consumption, marital 
status, education level, 
regular exercise, family 
history of coronary 
heart disease, baseline 
hypertension, diabetes 
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times/week), nearly 
every day, referring to 
the past one year. 
cholesterol, HDL, 
triglyceride, glucose, 
















1344 (51.5) 47.0 (14.4)M=11.8 (SD 
not reported) 
Difficulty initiating or 
maintaining sleep for ≥




based on the DSM-IV 
criteria; 
maintenance of an AHI 
< 5 and PLM< 15; and 
no sign of any other 
sleep disorder,  
such as narcolepsy or 
RBD, based on PSG. 
Death records 





110 Age, sex, sleep 
efficiency 
























4225 (70.8) 48.6 (14.1) M=10.5 (4.1) Difficulty initiating or 
maintaining sleep for ≥




based on the DSM-IV 
criteria; 
maintenance of an AHI 
< 5 and PLMI < 15; and 
no sign of any other 
sleep disorder,  
such as narcolepsy or 
RBD, based on PSG. 
 
Death records 





354 Age, sex, BMI, 
hypertension, diabetes. 
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CM) codes  
(weekend/weekday, 
bed size, ownership of 
hospital, 
location/teaching status 


















Study - II 
305,057 
(100) 
53.3 (7.9) 28 Self-reported - “On the 
average, how many 
times per month do you 
have insomnia?” 
Frequency of insomnia 
was classified as never; 
infrequent or 1, 2, 
3–9, and ≥10 
nights/month; or 
missing if left blank  
Deaths were 
identified and 
verified by 1) 
obtaining death 
certificates and 
2) linkage to the 
National Death 
Index 
4974 Age, race, education, 
BMI, smoking status, 




















recruited via 40 
clinical centres 
throught he US.  
158,203 
(0.0) 




Individuals are asked to 
indicate how many 
times per week they 
have had trouble falling 
asleep, waking up 
during the night, 
waking earlier than 
planned, trouble getting 
back to sleep, and rate 
the overall restfulness 






and via the 
National Death 
Index 
30,400 Age, smoking status, 
pack-years of smoking, 
alcohol intake, 
hormone therapy, BMI, 
red meat intake, 
physical activity, 
marital status, 
depression, history of 
diabetes, cancer, and 
cardiovascular disease, 
systolic blood pressure, 
health status, education 
level, ethnicity, study 
participation, sleep 
duration (hrs) and 
insomnia adjusted for 
use of sleep aids. 
All cause 
mortality, and 








































































1011 (60.4) 67.4 (14.7) M=2.19 (SD 
not reported) 
Insomnia was defined 
by several physicians as 
(1) usual use of 
hypnotics (“Do you 
take hypnotics more 
than 3 times per week”) 
or (2) presence of 
insomnia in addition to 
impairment of daytime 
function, based 
on ICSD-II criteria. 









151 Age, sex, New 
York Heart Association 
functional class III or 
IV, BMI, systolic 
blood pressure, heart 
rate, preserved LVEF, 
B-type natriuretic 
peptide, sodium, 




kidney disease, anemia, 
RAAS inhibitors, 
β-blockers, diuretics, 
inotropics and device 
therapy.  




















57.4 (10.6) 6 Self-report – “On the 
average, how many 




77, 639 Sleep duration, 
demographic risk 
factors, habits, health, 
medication use for 
sleep 





















































Self-report - (i) 
difficulties initiating 
sleep; (ii) nocturnal 
awakenings (sleep 
maintenance problems); 
and (iii) waking up too 
early. The reference 
time was the previous 4 
Statistics Finland 
and Norwegian 




















shift work, sleep 





























































weeks.  Suffering from 
insomnia symptoms 15 
nights or more often 
during the previous 4 
weeks was classified as 
having frequent 
insomnia. Others were 

















54279 (45.9) 44.6 (13.2) 11.3 (2.9)  Self-report – difficulty 
initiating sleep (“Have 
you had difficulties 
falling asleep in the last 
month?”), difficulty 
maintaining sleep 
(“During the last 
month, have you woken 
up too early and not 
been able to get back to 
sleep”) or non-
restorative sleep (“How 
often do you suffer 
from poor sleep?”). 
National cause of 
death registry. 
408 Age, sex, marital 
status, education, shift 
work, systolic blood 
pressure, total 
cholesterol, diabetes 
mellitus, BMI, physical 
activity, smoking, 
alcohol, previous acute 
myocardial infarction, 
depression, anxiety. 


















living in Hong 
Kong. 
3427 (50.9) 74.0 (4.7) 5.14 (0.2)  Self-report – Difficulty 
falling sleep, difficulty 
getting back to sleep 
after waking up at 
night, waking up too 
early or having trouble 
staying sleep, and non-
restorative sleep. 
Insomnia defined as 
answering “16 to 30 
nights per month” to 
any of these questions. 
Death registry 
kept by the 
Department of 






297 Age, medical 
conditions, smoking, 
use of sleep 
medications, insomnia, 
self-reported sleep 
apnea, daily napping, 
overweight, and frailty 
status 




























































based living in 
Tuscon, 
Arizona. 
1409 (45.1) 47.0 (14.0)20 Insomnia defined 
according to ISCD 
criteria including 
persistent symptoms of 
trouble falling asleep, 
staying asleep, or 
waking up too early in 
the morning – 
accompanied by at least 







318 Age, sex, BMI, 
smoking, pack-years of 
smoking, regular 
physical exercise and 
hypnotic use. 



























6236 (38.1) 42.6 (1.5) 13-15 Self-reported – 
Karolinska Sleep 
Questionnaire. 
Insomnia defined as 
meeting the DSM-IV 
criteria. Subjects were 
categorized as having 
insomnia if they 
reported problems with 
sleep onset, sleep 
maintenance, or early 
morning awakening (or 
a combination) “several 
times a week” or 
“ always” over the past 
three months, in 
addition to reporting 
daytime 
tiredness/sleepiness 





160 Age, sex, education, 
health behaviours, 







medication use, and 
sleep duration. 
 















in two counties 
of Central 
1741 (42.6) 48.6 (13.4) Male= 
13.9 (3.5) 
 
Self-reported - The 
presence of “insomnia” 




248 Age, race, education, 
BMI, smoking status, 
alcohol use, 




















































plaint of insomnia with 
a duration of at least 1 
year 
security numbers 
with 2 death 
record services: 
the U.S. Social 
Security Death 
Index and the 
Pennsylvania 


























151 (49.0) 64.6 (13.9)>3 (mean not 
reported) 
Self-reported – Athens 
Insomnia Scale based 
on ICD-10 criteria for 
insomnia.  

















AHI=Apnea Hyponea Index; BMI=Body Mass Index; DSM-VI=Diagnostic and Statistical Manual of Mental Disorde s, 4th edition; HDL=High-Density Lipoprotein; ICD=International Classification of 
Diseases; ICSD=International Classification of Sleep Disorders; IQ=Interquartile Range; LVEF=Left Ventricular Ejection Function; RAAS=Reserved Angiotensin Aldosterone System 
# Studies that included the presence of daytime impairments in their definition of insomnia. 
* For instances where the authors have not provided mean age, age range is stated. 
^ Weighted mean age +/- standard error 
x Quality ratings are based on the scale developed by Hayden et al. (2006) and scored across the following domains study participation,  study attrition; utcome measurement, confounding measurement, 







































Odds Ratio  
(95% CI)  
Weight,  
% 
Chen et al. 2013(56)  .09 (.06-.13) 7.2% 
Chien et al. 2010(22) 2.13 (1.35-3.39) 7.1% 
Choi et al. 2017(45) 1.60 (.87-2.93) 6.8% 
Choi et al. 2017(36) 2.01 (1.27-3.18) 7.1% 
Gamaldo et al. 2016(43) .28 (.27-.29) 7.5% 
Gapstur et al. 2014(26) 1.02 (.94-1.12) 7.4% 
Kanno et al. 2016(44) 1.26 (.89-1.79) 7.2% 
Kripke et al. 2002(27) 1.43 (1.36-1.52) 7.5% 
Lallukka et al. 2016(46) 1.70 (1.28-2.27) 7.3% 
Laugsand et al. 2014(47) .91 (.14-.27) 7.3% 
Lee et al. 2014(48) 6.99 (4.48-10.89) 7.1% 
Sivertsen et al. 2014(59) 2.80 (1.76-4.46) 7.1% 
Vgontzas et al. 2010(25) .81 (.52-1.27) 7.1 % 
Wang et al. 2017 (52) 1.64 (.71-1.84) 6.4% 
Total 1.06 (.61-1.84) 
Test for overall effect: Z= 0.20 (p=.84) 
 
Note: Open markers in forest plot denote studies that included the presence of daytime impairments in their 
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Forest plot for mortality risk in insomnia using hazard ratios from multivariate models with 




(95% CI)  
Weight, 
% 
Bertisch et al 2018(49) 0.99 (.77-1.27) 8.5% 
Chen et al. 2013(56)  0.64 (.43-.96) 4.9% 
Choi et al. 2017(45) .89 (.48-1.65) 2.5% 
Choi et al. 2017(42)  8.11 (1.03-63.72) 0.3% 
Kabat et al. 2018(50) 1.11 (1.07-1.15) 15.2% 
Kanno et al. 2016 (38) 1.90 (1.33-2.71) 5.7% 
Kripke et al.* 2002(27) 
- Male .94 (.91-.97) 15.2% 
- Female .86 (83-.89) 15.2% 
Lallukka et al.* 2016(46) 
- Male (Finland) 1.20 (.52-2.77) 2.1% 
- Female (Finland) .67 (.34-1.32) 2.3% 
- Male (Lithuania) 1.06 (.43-2.59) 1.3% 
- Female (Lithuania) 1.04 (.55-1.98) 0.9% 
- Male (Norway) 1.85 (.91-3.76) 2.0% 
- Female (Norway) 1.61 (.54-4.81) 1.5% 
Laugsand et al. 2014(47) 1.27 (.94-1.70) 7.1% 
Lee et al. 2014(48) 0.90 (.56-1.44) 3.9% 
Parthasarathy et al. 2015(51) 1.18 (.91-1.54) 8.0% 
Sivertsen et al. 2014(59) 3.34 (1.67-6.87) 2.1% 
Wang et al. 2017(52) 1.30 (.57-2.98) 1.5% 
Total 1.07 (.96-1.19) 
Test for overall effect: Z= 1.23 (p=.22) 
 
Note: Open markers in forest plot denote studies that included the presence of daytime impairments in heir 
definition of insomnia.*– HR reported separately for men and women in these studies. Lallukka and colleagues 
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Age  
- < 65 







































- < 5,000 
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Figure 2 – Funnel plot of meta-analysis using hazard ratios from multivariate models with the 
most complete adjustment for potential confounders 
Note the observed studies are shown by the open shapes and the studies imputed using the ‘Trim and Fill’ method 
are shown in the closed shapes 
 





















































Figure 1 – Flow of literature through the search process 
MEDLINE, OvidSP, 
PsycInfo, Pubmed 
search and reference 
lists  
(N= 438) 
88 papers excluded 
 
- No outcome measure of insomnia 
symptoms or mortality (N=36) 
- Insomnia symptoms not persistent 
(N=11) 
- No original data/review paper (N=39) 
- Death/survival data for the insomnia 
and no insomnia groups not provided 
(N=2) 
 
 -      Not relevant (N=333) 
Studies investigating the 
relationship between 
insomnia symptoms and 
mortality  
 
(N= 105) 
Papers included 
 
(N= 17) 
